FTC wants to know: How are PBMs affecting drug affordability and access?

msevcik1
Mar 4, 2022
1 min read

Following the Federal Trade Commission’s decision to not, at least initially, dig deeper into pharma middlemen known as PBMs, the commission is now seeking comments on ways that these massive, vertically integrated PBMs are affecting drug affordability and access.

Read the full story >

PBM Accountability Project Statement on Administration’s April 15 Executive Order

The White House issued an executive order (EO) on April 15 aimed at “Lowering Drug Prices by Once Again Putting Americans First.” The...

PBM Accountability Project Statement on Critical PBM Reforms in Congress

Many Congressional leaders and stakeholders continue to highlight the need for the PBM reforms. Representative Buddy Carter (R-GA)...

PBM Accountability Project Statement on House Introduction of Critical PBM Reforms

Representatives Mariannette Miller-Meeks, M.D. (R-IA), Nannette Barragan (D-CA), Nicole Malliotakis (R-NY), Brad Schneider (D-IL), Rick...